Evidence map›Paper›PMID 22951902›Full record

ReviewHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme2012

Prkar1a in the regulation of insulin secretion.

M A Hussain, C Stratakis, L Kirschner

Abstract readReview
In one paragraph

Review in Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Cyclic AMP, protein kinase A, and phosphodiesterases: proceedings of an international workshop.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

M A HussainDepartment of Pediatrics, Medicine and Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. mhussai4@jhmi.edu
C Stratakis
L Kirschner
Johns Hopkins Medicine · USThe Ohio State University · US

Funding

Molecular Genetics of Endocrine Tumors and Related DisordersZIAHD008920 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATAKIS, CONSTANTINE A. · 2012 to 2021
$25.8M
JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI AHIMA, REXFORD S. · 2013 to 2017
$9.7M
Diabetes Research and Training CenterP60DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WONDISFORD, FREDRIC E. · 2008 to 2012
$9.1M
Transcriptional coactivators and hepatic glucose productionR01DK063349 · NIDDK · UNIVERSITY OF CHICAGO · PI WONDISFORD, FREDRIC E. · 2002 to 2017
$5.0M
Beta-cell ProliferationR01DK081472 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI HUSSAIN, MEHBOOB A, WONDISFORD, FREDRIC E. · 2009 to 2013
$2.1M
Carney Complex: A Model for PKA-Mediated TumorigenesisR01CA112268 · NCI · OHIO STATE UNIVERSITY · PI KIRSCHNER, LAWRENCE S · 2004 to 2008
$1.3M
Intramural NIH HHS ZIA HD008920NCI NIH HHS CA112268NCI NIH HHS R01 CA112268NIDDK NIH HHS DK63349NIDDK NIH HHS DK79637NIDDK NIH HHS DK81472NIDDK NIH HHS DK84948NIDDK NIH HHS P30 DK079637NIDDK NIH HHS P60 DK079637NIDDK NIH HHS R01 DK063349NIDDK NIH HHS R01 DK081472
6 · The paper itself

Abstract

The incidence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide with significant consequences on individual quality of life as well as economic burden on states' healthcare costs. While origins of the pathogenesis of T2DM are poorly understood, an early defect in glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells is considered a hallmark of T2DM. Upon a glucose stimulus, insulin is secreted in a biphasic manner with an early first-phase burst of insulin, which is followed by a second, more sustained phase of insulin output. First phase insulin secretion is diminished early in T2DM as well is in subjects who are at risk of developing T2DM. An effective treatment of T2DM with incretin hormone glucagon-like peptide-1 (GLP-1) or its long acting peptide analogue exendin-4 (E4), restores first-phase and augments second-phase glucose stimulated insulin secretion. This effect of incretin action occurs within minutes of GLP-1/E4 infusion in T2DM humans. An additional important consideration is that incretin hormones augment GSIS only above a certain glucose threshold, which is slightly above the normal glucose range. This ensures that incretin hormones stimulate GSIS only when glucose levels are high, while they are ineffective when insulin levels are below a certain threshold. Activation of the GLP-1 receptor, which is highly expressed on pancreatic β-cells, stimulates 2 -distinct intracellular signaling pathways: a) the cAMP-protein kinase A branch and b) the cAMP-EPAC2 (EPAC=exchange protein activated by cAMP) branch. While the EPAC2 branch is considered to mediate GLP-1 effects on first-phase GSIS, the PKA branch is necessary for the former branch to be active. However, how these 2 branches interplay and converge and how their effects on insulin secretion and insulin vesicle exocytosis are coordinated is poorly understood.Thus, at the outset of our studies we have a poorly understood intracellular interplay of cAMP-dependent signaling pathways, which - when stimulated - restore glucose-dependent first phase and augment second phase insulin secretion in the ailing β-cells of T2DM.

Indexed as

AnimalsCyclic AMP-Dependent Protein Kinase RIalpha SubunitDiabetes MellitusExocytosisHumansInsulinInsulin-Secreting CellsInsulin SecretionVesicular Transport ProteinsCyclic AMP-Dependent Protein Kinase RIalpha SubunitInsulinVesicular Transport Proteins

Identifiers

PMID22951902
PMCPMC4034137
OpenAlexW1967246304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.